Research Analysts Set Expectations for argenx Q2 Earnings

argenx SE (NASDAQ:ARGX - Free Report) - Analysts at William Blair boosted their Q2 2025 earnings per share (EPS) estimates for shares of argenx in a research report issued to clients and investors on Thursday, May 29th. William Blair analyst M. Minter now anticipates that the company will earn $2.36 per share for the quarter, up from their prior forecast of $2.12. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx's Q3 2025 earnings at $2.76 EPS, Q4 2025 earnings at $3.12 EPS, FY2025 earnings at $10.68 EPS, Q1 2026 earnings at $4.32 EPS, Q2 2026 earnings at $4.85 EPS, Q3 2026 earnings at $6.33 EPS, Q4 2026 earnings at $7.29 EPS and FY2026 earnings at $22.81 EPS.

ARGX has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Citigroup reissued a "buy" rating on shares of argenx in a report on Wednesday, May 21st. Guggenheim decreased their target price on argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Baird R W raised argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Wells Fargo & Company boosted their target price on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $709.18.

argenx Trading Up 2.0%

Shares of argenx stock traded up $11.34 on Monday, reaching $584.60. 275,914 shares of the company were exchanged, compared to its average volume of 323,285. The company has a market capitalization of $35.70 billion, a price-to-earnings ratio of -664.32 and a beta of 0.57. argenx has a one year low of $368.57 and a one year high of $678.21. The company has a 50-day moving average of $586.57 and a 200 day moving average of $612.64.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million.

Institutional Trading of argenx

A number of institutional investors have recently modified their holdings of the stock. GeoWealth Management LLC raised its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in shares of argenx during the 4th quarter worth $37,000. Global Retirement Partners LLC lifted its position in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in argenx in the fourth quarter valued at about $38,000. Finally, Rakuten Securities Inc. grew its position in argenx by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after acquiring an additional 22 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.